EU Authorized Representative for Thailand: Latex, Rubber-Derived Devices and Thai FDA Tiers
Thai FDA issues one of three certificates depending on where a device falls across four risk classes - listed, notified or licensed - and for some product groups a selling licence on top. None of those is a conformity assessment, and none of them travels. For the rubber-derived lines that Thailand is known for, the harder surprise is elsewhere: Regulation (EU) 2017/745 never mentions latex, and instead pushes the whole question into materials and residue evidence under Annex I. This page sets out what that costs and where the Thai file still helps.
Listed, notified, licensed — three certificates, none of them a conformity assessment
Thailand’s framework under the Medical Device Act B.E. 2551 (2008), as amended by the Medical Device Act (No. 2) B.E. 2562 (2019), sorts devices into four risk classes and issues a different instrument for each band: a Certificate of Listed Medical Device for Class 1, a Certificate of Notified Medical Device for Classes 2 and 3, and a Certificate of Licensed Medical Device for Class 4. Manufacturing or importing requires an establishment licence alongside the product certificate, and a further group of products — dental implants, brackets, braces and aligners, etching, filling and cementing materials, impression materials, artificial teeth and fluoride varnish among them — additionally requires a selling licence.
Every one of those is a permission to trade in Thailand. None of them is a conformity assessment within the meaning of MDR Article 52, none produces a certificate a notified body may rely on, and a Class 4 licence does not indicate class III in the Union any more than Class 1 indicates class I. The Thai classification derives from the ASEAN risk rules; MDR Annex VIII runs to twenty-two rules with its own duration definitions and its own strictest-rule-wins principle in Chapter II.
The Regulation never once says the word latex
For a country whose device exports are heavily rubber-derived, this is the most useful thing to know about MDR before opening a file. Search the full text of Regulation (EU) 2017/745 for latex and there is nothing. The Regulation contains no dedicated latex clause, no prescribed symbol and no reserved wording. Manufacturers who arrive expecting a labelling rule to comply with find instead that the burden has been moved upstream, into the general safety and performance requirements, where it is much heavier and much harder to close with a sentence on a carton.
Annex I Section 10.1 requires that particular attention be paid, among other things, to "the compatibility between the materials and substances used and biological tissues, cells and body fluids, taking account of the intended purpose of the device and, where relevant, absorption, distribution, metabolism and excretion;" (MDR Annex I, Chapter II, Section 10.1(b)) Section 10.2 then requires devices to be designed, manufactured and packaged so as to minimise the risk from contaminants and residues, with particular attention to the tissues exposed and to the duration and frequency of exposure.
Protein residues and accelerators are a materials file, not a warning line
Applied to natural rubber latex, those two sections ask for a body of evidence rather than a statement. Extractable protein levels have to be characterised for the compound as actually produced, and controlled as a specification with an established test method, because leachable protein is the recognised hazard rather than latex as an abstract material. Vulcanisation accelerator residues — thiurams, carbamates, benzothiazoles — belong in the same analysis, since they drive delayed contact reactions that a protein assay will not detect.
A biological evaluation under Annex I Section 10.1 then has to bring those characterisation results together with the contact type and duration for the specific device, and be maintained as the compound changes. Two further habits catch Thai files out. Ageing behaviour is compound-specific, so shelf-life justification cannot be inherited from a different formulation or a different supplier’s dipping line. And hypoallergenic, or any equivalent reassurance, is a claim that must be substantiated on the evidence in the file or removed from every piece of labelling and promotional material.
Rubber-derived lines against Annex VIII
The classification outcomes are less uniform than a single material suggests. Contraceptive devices in particular carry a rule of their own: "All devices used for contraception or prevention of the transmission of sexually transmitted diseases are classified as class IIb, unless they are implantable or long term invasive devices, in which case they are classified as class III." (MDR Annex VIII, Chapter III, Rule 15)
| Product line | Annex VIII rule | MDR class | What that means in practice |
|---|---|---|---|
| Condom | Rule 15 | IIb | Full notified body assessment including technical documentation review |
| Urinary catheter, transient use | Rule 5, first indent | I | Self-declared, but sterile presentation brings a notified body in for sterility |
| Indwelling urinary catheter, short-term use | Rule 5, second indent | IIa | Notified body assessment under Annex IX Chapters I and III, or Annex XI |
| Dental impression material | Rule 5, oral cavity carve-out | I | Self-declared; the carve-out applies as far as the pharynx |
| Dental implant | Annex VIII implantable rules | IIb or III depending on the rule applied | Assessment of the technical documentation for the specific device |
Thailand’s dental block meets a different rulebook
The dental group that Thailand singles out for a selling licence is also the group that behaves least predictably under Annex VIII, because the products straddle several rules at once. Impression materials sit in Rule 5 and stay class I under the oral-cavity carve-out. Filling and cementing materials are surgically invasive in use and are examined on their chemistry as much as their mechanics. Implants are implantable devices and attract technical documentation assessment on the device itself, not on a representative sample of a family. A Thai portfolio that is administratively homogeneous — one selling licence category — becomes three or four different European projects, and pricing the work off the Thai grouping produces a budget that is wrong from the first week. Our published class-based fees are set the same way the Regulation is, by class.
One Thai-language label does not scale to the Union
Thai labelling and package insert requirements are set nationally and satisfied in one language. In the Union each Member State determines the official language or languages in which the information accompanying the device must be supplied, and the duty sits with the manufacturer rather than with whoever sells there. For a rubber-derived product the translated content is not trivial: warnings and precautions under Annex I Section 23.2(m), single-use indication under 23.2(n), sterile state and sterilisation method under 23.2(l), and the instructions for use content required by Section 23.4 including residual risks and contraindications. Each language version is a controlled document that has to be re-issued when the compound, the process or the intended purpose changes.
Running the mandate from Bangkok or Rayong
Under MDR Article 11(1) a manufacturer outside the Union reaches the market only through a single designated representative, and the designation takes effect when accepted in writing. Medex acts under EUDAMED authorised representative SRN TR-AR-000057550, and is separately registered as a manufacturer, TR-MF-000057496, and as an importer. The person responsible for regulatory compliance is in-house — a partner of the firm, with a deputy — so the Article 15 expertise requirement is met by named individuals. Offices are in Ankara, İstanbul and Gdańsk. Actor and device registration runs alongside the mandate; see EUDAMED registration.
What Thai manufacturers ask before the first submission
We hold a Thai FDA licence for this product. What does it do for us in Europe?
Nothing procedurally. It does not shorten a notified body review, satisfy any Annex, or establish a class. The technical evidence assembled to obtain it — sterilisation validation, biocompatibility, physical performance testing, stability data — is a different matter and usually covers a meaningful share of what Annex II asks for.
Is it enough to state on the label that the device contains natural rubber latex?
A statement may well be appropriate, but it is not what the Regulation is asking for. MDR does not name latex at all; it requires that materials compatibility with tissues and body fluids be addressed under Annex I Section 10.1, and that contaminants and residues be minimised under Section 10.2. That is a characterisation and biological evaluation exercise, and the label follows from it rather than substituting for it.
Our condoms are Class 4 in Thailand. Are they class III in Europe?
No. Rule 15 puts contraceptive devices in class IIb unless they are implantable or long-term invasive. That is still a full notified body route with assessment of the technical documentation, but it is not class III, and the two classifications are reached by entirely separate rule sets that happen to sit at similar points on their own scales.
Can we appoint a representative before the technical file is finished?
Yes, and there are good reasons to. The mandate has to be in place before the device is placed on the market, not before the file is assembled, and having the representative involved during preparation means the Annex I checklist, the labelling and the registration data are built once rather than reworked. Send us the product list and the destination markets and we will tell you which parts of your Thai dossier travel.